Alopecia areata (AA) is a T-cell–mediated autoimmune disease. Efalizumab is a T-cell–targeted therapy approved for the treatment of psoriasis.
To assess the efficacy and safety of efalizumab in the treatment of moderate-to-severe AA.
Sixty-two patients were enrolled into this phase II, placebo-controlled trial. The trial consisted of three 12-week periods—a double-blind treatment period, an open-label efalizumab treatment period, and a safety follow-up.
There were no statistical differences between treatment groups in percent hair regrowth, quality-of-life measures, or changes in biologic markers of disease severity after 12 or 24 weeks. In both groups, there was an approximately 8% response rate for hair regrowth (at 12 weeks). Efalizumab was well tolerated.
Numbers were too small for certain analyses.
A 3- to 6-month trial of efalizumab was not effective in promoting hair regrowth in this small cohort of patients with moderate-to-severe AA.Le texte complet de cet article est disponible en PDF.
| Presented at the 2006 Society for Investigative Dermatology Annual Meeting, Philadelphia, PA, May 3-6, 2007.
| Supported by Genentech, Inc.
| Disclosures: Dr Price has received grant support and served as an investigator for Xoma and Genentech, Inc. Dr Hordinsky has received grant support and served as an investigator for Astellas and Genentech, Inc. Dr Roberts has received research support and is an investigator for Abbott. Dr Siegfried has been a paid investigator and received honoraria for Genentech, Inc. Dr Rafal has received grant support and served as an investigator for Serono International SA, Amgen, Biogen Idec, and Genentech, Inc. Drs Olsen and Altrabulsi have no conflicts of interest to disclose. Dr Korman has received grant support and honoraria and served as a speaker, consultant, and an advisory board member for Astellas and Novartis; he is an investigator for Novartis. Dr Leung is a stock shareholder and an employee of Xoma. Dr Garovoy is a stock shareholder and was an employee of Xoma, and has been a consultant of Genentech, Inc. Dr Caro is a stock shareholder and an employee of Genentech, Inc. Dr Whiting is an investigator for Xoma and Genentech, Inc.